BeyondSpring Announces First Patient Treated in Phase II Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors

BeyondSpring announced the first patient has been treated in an investigator-initiated, open-label Phase II study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3^rd line recurrent small-cell lung cancer who failed checkpoint inhibitors and platinum-based chemotherapy.